Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review addresses the signaling of ERβ and GPER in ERα-negative breast tumors.
|
30687231 |
2018 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction.
|
28808484 |
2017 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The human ERβ variant ERβ2 is proposed to be expressed at higher levels than ERβ1 in many breast tumors and it has been suggested that ERβ2, in contrast to ERβ1, is associated with aggressive phenotypes of various cancers.
|
29100336 |
2017 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upregulation of estrogen receptor beta (ERβ) in breast cancer cells is associated with epithelial maintenance, decreased proliferation and invasion, and a reduction in the expression of the receptor has been observed in invasive breast tumors.
|
28673316 |
2017 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, when combined with MSI/LOH in AR, ERβ and CYP19 genes, we were able to detect significant associations with the GSTP1 wild-type genotype in PR (progesterone receptor) negative breast cancers or the CYP17 wild-type genotype in ER (estrogen receptor) and PR-negative breast tumors.
|
28692125 |
2017 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The HYAL1 repression was also specific to ERα and not to ERβ, whose expression did not correlate with HYAL1 in human breast tumors.
|
27764788 |
2016 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Obesity is associated with a worse breast cancer prognosis, while greater breast tumor estrogen receptor beta (ERβ) expression is correlated with improved therapy response and survival.
|
26709918 |
2015 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells.
|
24960160 |
2014 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The second ER, ERβ, is also expressed in breast tumors, but its function and therapeutic potential need further study.
|
24192230 |
2014 |
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
In general, ERβ promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia (44.9% vs. 14.3%, X(2) = 4.986, P = 0.026).
|
22105146 |
2012 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data demonstrate that PES1 contributes to breast tumor growth through regulating the balance between ERα and ERβ and may be a better target for the development of drugs that selectively regulate ERα and ERβ activities.
|
22820289 |
2012 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of ERβ in breast tumors has been implicated as an indicator of tamoxifen sensitivity.
|
21492444 |
2011 |
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
|
19434490 |
2010 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
|
19434490 |
2010 |
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
"c-erbB-2 and the ""triple-state"" in early breast carcinomas."
|
19548127 |
2010 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
"c-erbB-2 and the ""triple-state"" in early breast carcinomas."
|
19548127 |
2010 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
|
18669459 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
|
18698041 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
|
18216219 |
2008 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.
|
17904846 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
|
17415682 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
|
18234277 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.
|
17428314 |
2007 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Estrogen receptor-beta: why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer?
|
17617929 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer.
|
17203178 |
2007 |